Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 10/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959702 | 0.91 | TRPM8 (0.48) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL4901333 | 0.88 | TRPM8 (0.56) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3963601 | 0.88 | TRPM8 (0.56) | TRPM8PPARGPPARAPPARD | |
| Tert-Butylamine SCHEMBL3963133 | 0.85 | TRPM8 (0.55) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3963050 | 0.84 | PPARA (0.57) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3961870 | 0.82 | TRPM8 (0.47) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3963569 | 0.82 | TRPM8 (0.55) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3959919 | 0.81 | PPARA (0.54) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3966524 | 0.80 | PPARA (0.59) | TRPM8PPARGPPARAPPARD | |
| SCHEMBL3968760 | 0.79 | PPARA (0.56) | TRPM8PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7462644-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | TRPM8 4238/4885PPARG 479/4885PPARA 539/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | TRPM8 4071/4885PPARG 228/4885PPARA 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.